Newsletter January 2021 No.201

Top News

The 7th Nikkei-FT Conference on Infectious Diseases" Pharmaceutical Manufacturers Association of Japan (PMAJ) Lunch Session - Proposal to strengthen future infectious disease control measures through industry-academia-government collaboration

The worldwide spread of novel coronavirus infection (COVID-19) is having a tremendous impact on global society and the economy. On June 17, 2020, the Pharmaceutical Manufacturers Association of Japan (PMAJ) compiled and disseminated the "PMAJ Proposal for the Creation of Therapeutic Agents and Vaccines for Infectious Diseases". The proposal is designed to overcome the challenges of preparing for future unknown infectious diseases, while promoting activities based on a strong awareness of our mission as an R&D-oriented pharmaceutical company, which is the early creation of treatments and vaccines and the stable supply of pharmaceutical products. The proposal emphasizes the importance of further collaboration between industry, academia, and government in order to strengthen infectious disease countermeasures in Japan. The Pharmaceutical Manufacturers Association of Japan (PMAJ) is working to realize the proposal, and as part of this effort, participated in the "7th Nikkei-FT Conference on Infectious Diseases" (online conference format) and held a PMAJ lunch session on November 7, the second day of the conference. In this session, key persons from industry, academia, and government presented information on how Japan should respond in the future for the rapid discovery and supply of drugs and vaccines for infectious diseases, preparedness in normal times, necessary functions, international cooperation, and other issues.

Topics

Policy Research Institute page

From JPMA

New Year's Message for 2021

Information

Share this page

TOP